Table 2.
Expression of costimulatory molecules on patients’ purified myeloma cells
| Patient N° | Percentage of labeled myeloma cells | |||||||
|---|---|---|---|---|---|---|---|---|
| 4-1 BBL | 4-1 BB | B7-1 | B7-2 | CD28 | CD70 | CD27 | CD40 | |
| 1 | 5.5 | <0.5 | <0.5 | 20 | 10 | <0.5 | 79 | 100 |
| 2 | <0.5 | <0.5 | <0.5 | 25 | 10 | <0.5 | 86 | 100 |
| 3 | <0.5 | <0.5 | <0.5 | 80 | 6 | <0.5 | 34 | 90 |
| 4 | <0.5 | <0.5 | <0.5 | 25 | 28 | <0.5 | 55 | 75 |
| 5 | <0.5 | <0.5 | <0.5 | 87 | 2 | <0.5 | 90 | 100 |
| 6 | <0.5 | <0.5 | <0.5 | 91 | 2 | <0.5 | 100 | 100 |
| 7 | <0.5 | <0.5 | <0.5 | 34 | 5 | <0.5 | <0.5 | 100 |
Patients’ myeloma cells were purified and stained with the indicated PE-conjugated mAb or PE-conjugated control mAb. The fluorescence was analyzed with a FACSscan device. Data are the percentages of labeled cells.